Suchergebnisse - "Corte, Tamera J"

PubPharm (6)

1

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

enthalten in: BMJ open respiratory research | 2021

von Corte, T. | Lancaster, L. | Swigris, J. | +14

2

TELO-SCOPE study : a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis

enthalten in: BMJ open respiratory research | 2021

von Mackintosh, J. | Pietsch, M. | Lutzky, V. | +17

3

Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia : A post hoc subgroup analysis of the RISE-IIP study

enthalten in: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation | 2021

von Nathan, S. | Cottin, V. | Behr, J. | +16

4

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : a double-blind, randomised, placebo-controlled, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2020

von Maher, T. | Corte, T. | Fischer, A. | +8

CommentIn: Lancet Respir Med. 2020 Feb;8(2):126-127. - PMID 31578170

5

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials

enthalten in: The European respiratory journal | 2019

von Noth, I. | Wijsenbeek, M. | Kolb, M. | +4

6

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP) : a randomised, placebo-controlled phase 2b study

enthalten in: The Lancet. Respiratory medicine | 2019

von Nathan, S. | Behr, J. | Collard, H. | +12

CommentIn: Lancet Respir Med. 2019 Sep;7(9):727-728. - PMID 31416766

1
[1]